The FDA approved Eli Lilly's Foundayo (tirzepatide oral) today, marking a pivotal moment in the $100 billion weight loss medication market. The approval comes just six months after Novo Nordisk's oral Wegovy received clearance, setting up a direct head-to-head competition between pharmaceutical giants.
Clinical Trial Results
In Phase III trials involving 2,400 participants, Foundayo demonstrated an average weight loss of 11.2% over 68 weeks, compared to 2.1% with placebo. The results, published simultaneously in The New England Journal of Medicine, show Foundayo trailing slightly behind oral Wegovy's 12.8% efficacy rate.
"This approval represents the first real competition in the oral GLP-1 space. Patients will benefit from having alternatives, and market dynamics will inevitably drive down costs." — Dr. Amanda Rodriguez, Obesity Medicine Specialist
Pricing Strategy
Eli Lilly set Foundayo's list price at $1,200 per month, $200 less than oral Wegovy's $1,400 monthly cost. Industry analysts expect aggressive pricing competition as both companies vie for insurance formulary inclusion.
Market Impact
The approval triggered immediate market reactions:
- Eli Lilly stock jumped 7.2% in after-hours trading
- Novo Nordisk shares fell 3.8% on Copenhagen exchange
- Compounding pharmacy stocks continued their decline, with Hims & Hers down an additional 5%
Clinical Considerations
Healthcare providers note key differences between the medications. Foundayo showed a slightly higher incidence of gastrointestinal side effects (68% vs 62% for oral Wegovy) but demonstrated better glycemic control in diabetic patients.
The approval also includes a comprehensive Risk Evaluation and Mitigation Strategy (REMS) requiring prescriber certification and patient counseling on potential thyroid risks.
Looking Ahead
With both oral options now available, the focus shifts to real-world effectiveness and insurance coverage decisions. Medicare coverage remains prohibited under current law, leaving millions of potential patients reliant on private insurance or out-of-pocket payments.
Eli Lilly plans to launch Foundayo in major metropolitan areas by June 2026, with national availability expected by September.
Hey, do you want Retatrutide?
Stop waiting for the next generation of weight loss and stop dealing with generic telehealth clinics. Get physician-led access to Retatrutide, comprehensive labs, and personalized optimization protocols.